

| שם תכשיר בעברית | שם תכשיר באנגלית | מספר רישום |
|--------------------------|-------------------------|-----------------|
| אביליפיי מיינטנה 300 מ"ג | ABILIFY MAINTENA 300 MG | 153-68-34089-00 |
| אביליפיי מיינטנה 400 מ"ג | ABILIFY MAINTENA 400 MG | 153-69-34094-00 |
| אדמפס 0.5 מ"ג | ADEMPAS 0.5MG | 153-76-34132-00 |
| אדמפס 1 מ"ג | ADEMPAS 1 MG | 153-77-34137-00 |
| אדמפס 1.5 מ"ג | ADEMPAS 1.5 MG | 153-78-34138-00 |
| אדמפס 2 מ"ג | ADEMPAS 2 MG | 153-79-34139-00 |
| אדמפס 2.5 מ"ג | ADEMPAS 2.5 MG | 153-80-34150-00 |

| | | |
|---------------------|---------------------|-----------------|
| | | 153-62-34091-00 |
| אטורבה טבע © 10 מ"ג | ATORVA TEVA © 10 MG | 153-63-34092-00 |

| | | |
|---------------------|---------------------|-----------------|
| | | |
| אטורבה טבע © 40 מ"ג | ATORVA TEVA © 40 MG | 153-61-34090-00 |
| | | |
| אטורבה טבע © 80 מ"ג | ATORVA TEVA © 80 MG | 153-60-34088-00 |
| בטמיגה 25 מ"ג | BETMIGA 25 MG | 153-46-34104-00 |
| | | |
| בטמיגה 50 מ"ג | BETMIGA 50 MG | 153-47-34113-00 |
| ברינטליקס 10 מ"ג | BRINTELLIX 10 MG | 153-73-34155- |
| ברינטליקס 15 מ"ג | BRINTELLIX 15 MG | 153-74-34156- |
| ברינטליקס 20 מ"ג | BRINTELLIX 20 MG | 153-75-34157- |
| ברינטליקס 5 מ"ג | BRINTELLIX 5 MG | 153-72-34152- |

| | | |
|---------------------------------------|---|-----------------|
| קנידריל 100 מ"ג טבליות לכלבים וטרינרי | CANIDRYL 100 MG TABLETS FOR DOGS VETERINARY | 153-51-33972-00 |
| קנידריל 50 מ"ג טבליות לכלבים וטרינרי | CANIDRYL 50 MG TABLETS FOR DOGS VETERINARY | 153-50-33967-00 |
| דופלקס 5/80 | DUPLEX 5/80 | 153-59-34303-00 |
| אנטיביו | ENTYVIO | 153-58-34277-00 |
| אקסווירה 250 מ"ג טבליות | EXVIERA 250 MG TABLETS | 153-56-34256-00 |
| פנליפס קולור | FENLIPS COLOR | 153-66-34008-00 |
| אייבו לילדים בטעם תות שדה | I BOO FOR CHILDREN STRAWBERRY FLAVOR | 153-81-34080-00 |
| איקלוסיג 15 מ"ג | ICLUSIG 15 MG | 153-53-34243-00 |
| איקלוסיג 45 מ"ג | ICLUSIG 45 MG | 153-54-34244-00 |
| ג'נס | JANESS | 153-52-34106-00 |
| אופדיבו 10 מ"ג/מ"ל | OPDIVO 10 MG/ML | 153-55-34333-00 |
| אוקסליפלטין " אבווה " 5 מ"ג/מ"ל | OXALIPLATIN " EBEWE" 5MG/ML | 153-71-33824-00 |
| פרצטאמול ב.בראון 10 מ"ג/מ"ל | PARACETAMOL B. BRAUN 10 MG/ML | 153-65-34064-00 |
| פבוראן | PHEBURANE | 153-57-34275-00 |
| רופיקאין ביאבניר 2 מ"ג/מ"ל | ROPIVACAINE BIOAVENIR 2 MG/ML | 153-67-33924-00 |

| | | |
|---|--------------------------------------|-----------------|
| טימודור | TIMODOR | 153-70-34076-00 |
| טריומק | TRIUMEQ | 153-49-34304-00 |
| ירומיטקסן 400 מ"ג | UROMITEXAN 400 MG | 153-48-34007-00 |
| ויקירקס 12.5 מ"ג / 75 מ"ג / 50 מ"ג טבליות | VIEKIRAX 12.5 MG/75 MG/50 MG TABLETS | 153-64-34257-00 |

| לטיפול ב |
|-------------------------------------|
| סכיזופרניה |
| סכיזופרניה |
| יתר לחץ דם ריאתי טרומבואמבולי כרוני |
| יתר לחץ דם ריאתי טרומבואמבולי כרוני |
| יתר לחץ דם ריאתי טרומבואמבולי כרוני |
| יתר לחץ דם ריאתי טרומבואמבולי כרוני |
| יתר לחץ דם ריאתי טרומבואמבולי כרוני |

הפרעות שומני הדם

הפרעות שומני הדם

הפרעות שומני הדם

הפרעות שומני הדם

תכיפות והגברה במתן שתן אצל מטופלים עם שלפוחית רגיזה

תכיפות והגברה במתן שתן אצל מטופלים עם שלפוחית רגיזה

דיכאון

דיכאון

דיכאון

דיכאון

| |
|--|
| בכלבים הסובלים מבעיות שריר שלד ומחלות שחיקת מפרקים |
| בכלבים הסובלים מבעיות שריר שלד ומחלות שחיקת מפרקים |
| ביתר לחץ דם |
| טיפול בדלקת כיבית של המעי הגס |
| בדלקת כבד ויראלית מסוג הפטיטיס C |
| טיפול חיצוני בפצעי קור (הרפס) |
| הורדת חום והקלה על כאב קל עד בינוני |
| ליוקמיה מיאלואידית כרונית (CML) |
| ליוקמיה מיאלואידית כרונית (CML) |
| אמצעי מניעה עד לשלוש שנים |
| מלנומה מתקדמת |
| טיפול משלבי לסרטן המעי אחרי הוצאת גידול, סרטן קולורקטלי גרורתי, טיפול משלבי בסרטן לבלב גרורתי. |
| טיפול קצר מועד בכאב בינוני במיוחד לאחר ניתוחים, טיפול קצר מועד בחום. |
| מחלות מעגל האוריאה |
| הרדמה ניתוחית (אפידורלית או פריפרית), טיפול בכאב |

לחץ תוך עיני מוגבר במטופלים עם יתר לחץ דם
עיני, גלאוקומה בזוית פתוחת וסוגים נוספים של
גלאוקומה

HIV

טיפול מגן על שלפוחית השתן בזמן טיפול
כימותרפי

בדלקת כבד ויראלית מסוג הפטיטיס C

התויה

Abilify Maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

Abilify Maintena is indicated for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with • inoperable CTEPH, • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.

Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with • inoperable CTEPH, • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.

Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with • inoperable CTEPH, • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.

Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with • inoperable CTEPH, • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.

Chronic thromboembolic pulmonary hypertension (CTEPH) Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III with • inoperable CTEPH, • persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity. Pulmonary arterial hypertension (PAH) Adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity. Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.

Atorva Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL-cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorva Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorva Teva is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains ≥ 190 mg/dl or 2. LDL-C remains ≥ 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event such as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorva Teva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.

Atorva Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL-cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorva Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorva Teva is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains ≥ 190 mg/dl or 2. LDL-C remains ≥ 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event such as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorva Teva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.

Atorva Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL-cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorva Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorva Teva is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains ≥ 190 mg/dl or 2. LDL-C remains ≥ 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event such as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorva Teva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.

Atorva Teva is indicated as an adjunct to diet for reduction of elevated total cholesterol LDL-cholesterol apolipoprotein B and triglycerides and to increase HDL Cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. Atorva Teva is also indicated to reduce total-C and LDL -C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. LDL apheresis) or if such treatments are unavailable. Pediatric patients (10-17 years of age) : Atorva Teva is indicated as an adjunct to diet to reduce total -C LDL-C and apo B levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains ≥ 190 mg/dl or 2. LDL-C remains ≥ 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient. Prevention of cardiovascular and/or cerebrovascular event such as MI or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. In patients with clinically evident coronary heart disease Atorva Teva is indicated to : Reduce the risk of non-fatal myocardial infarction. Reduce the risk of fatal and non fatal stroke. Reduce the risk for revascularization procedures. Reduce the risk of hospitalization for CHF. Reduce the risk of angina.

Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome

Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome

Brintellix is indicated for the treatment of major depressive episodes in adults.

Brintellix is indicated for the treatment of major depressive episodes in adults.

Brintellix is indicated for the treatment of major depressive episodes in adults.

Brintellix is indicated for the treatment of major depressive episodes in adults.

| |
|--|
| In Dogs; Reduction of inflammation and pain caused by musculo-skeletal disorders & degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain. |
| In Dogs; Reduction of inflammation and pain caused by musculo-skeletal disorders & degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain. |
| Treatment of essential hypertension. Duplex is indicated for patients whose blood pressure is not adequately controlled on monotherapy. |
| Ulcerative Colitis: Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNF α) antagonist. Crohn's Disease: Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNF α) antagonist. |
| Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults |
| For the topical treatment for cold sores (oral herpes) |
| For the reduction of fever and relief of mild to moderate pain. |
| Iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation • Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. |
| Iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation • Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. |
| Contraception for up to 3 years. |
| Opdivo is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. |
| Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for: - Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor. - Treatment of metastatic colorectal cancer. - Oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first-line treatment of patients with metastatic pancreatic adenocarcinoma (based on NCCN guidelines, version 2.2014) |
| Paracetamol is indicated for the short-term treatment of moderate pain, especially following surgery and for the short-term treatment of fever, when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible. |
| PHEBURANE is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. |
| Surgical anaesthesia: epidural block for surgery, including caesarean section. Peripheral nerve blocks . Acute pain management: continuous epidural infusion or intermittent bolus administration e.g. post operative or labour pain. Field block. |

For the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension, open-angle glaucoma, or other secondary open-angle glaucoma when concomitant therapy is appropriate.

Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

Prevention of urinary passage toxicity of oxazaphosphorines (the active components of Holoxan, Ifosfamide , Endoxan, Cyclophosphamide, Ixoten, Trofosamide), in particular in high-risk patients with previous radiation therapy in the area of the lesser pelvis, cystitis with previous Holoxan, Endoxan or Ixoten , urinary passage diseases in anamnesis.

Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults

| בעל רישום | יצרן |
|---------------------|--------------------------|
| LUNDBECK ISRAEL LTD | H.LUNDBECK A/S, DENMARK |
| LUNDBECK ISRAEL LTD | H.LUNDBECK A/S, DENMARK |
| BAYER ISRAEL LTD | BAYER PHARMA AG, GERMANY |
| BAYER ISRAEL LTD | BAYER PHARMA AG, GERMANY |
| BAYER ISRAEL LTD | BAYER PHARMA AG, GERMANY |
| BAYER ISRAEL LTD | BAYER PHARMA AG, GERMANY |
| BAYER ISRAEL LTD | BAYER PHARMA AG, GERMANY |

| | |
|--------------------------------|------------------------------------|
| | |
| TEVA PHARMACEUTICAL INDUST.LTD | TEVA PHARMACEUTICAL INDUSTRIES LTD |
| | |
| TEVA PHARMACEUTICAL INDUST.LTD | TEVA PHARMACEUTICAL INDUSTRIES LTD |

| | |
|------------------------------------|---|
| | |
| TEVA PHARMACEUTICAL INDUST.LTD | TEVA PHARMACEUTICAL INDUSTRIES LTD |
| | |
| TEVA PHARMACEUTICAL INDUST.LTD | TEVA PHARMACEUTICAL INDUSTRIES LTD |
| ASTELLAS PHARMA INTERNATIONAL B.V. | ASTELLAS PHARMA EUROPE B.V, THE NETHERLANDS |
| | |
| ASTELLAS PHARMA INTERNATIONAL B.V. | ASTELLAS PHARMA EUROPE B.V, THE NETHERLANDS |
| LUNDBECK ISRAEL LTD | H.LUNDBECK A/S, DENMARK |
| LUNDBECK ISRAEL LTD | H.LUNDBECK A/S, DENMARK |
| LUNDBECK ISRAEL LTD | H.LUNDBECK A/S, DENMARK |
| LUNDBECK ISRAEL LTD | H.LUNDBECK A/S, DENMARK |

| | |
|--|--|
| A.L. MEDI-MARKET LTD. | CHANELLE PHARMACEUTICALS LTD, IRELAND |
| A.L. MEDI-MARKET LTD. | CHANELLE PHARMACEUTICALS LTD, IRELAND |
| UNIPHARM LTD | TRIMA ISRAEL PHARMACEUTICAL PRODUCTS MAABAROT LTD, ISRAEL |
| TAKEDA ISRAEL LTD | TAKEDA ITALIA |
| ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL | ABBVIE LTD, UK |
| NUTRITION CONSUMER HEALTH | NOVARTIS CONSUMER HEALTH SCHWEIZ AG, SWITZERLAND |
| ABIC MARKETING LTD | FARMALIDER S.A., SPAIN |
| A.P.I. ARIAD PHARMACEUTICALS (ISRAEL) LTD | ARIAD PHARMA LTD, UK |
| A.P.I. ARIAD PHARMACEUTICALS (ISRAEL) LTD | ARIAD PHARMA LTD, UK |
| BAYER ISRAEL LTD | BAYER OY, FINLAND |
| BRISTOL - MYERS SQUIBB, ISRAEL | BRISTOL - MYERS SQUIBB HOLDINGS PHARMA, LTD, PUERTO RICO |
| PHARMALOGIC LTD | EBEWE PHARMA GES.M.B.H NFG.KG, AUSTRIA |
| LAPIDOT MEDICAL IMPORT AND MARKETING LTD | B.BRAUN MELSUNGEN AG, GERMANY |
| TRUEMED LTD, ISRAEL | LUCANE PHARMA , FRANCE |
| BIOAVENIR LTD, ISRAEL | L.MOLTENI & C. DEI F.LLI ALITTI,ITALY |

| | |
|---------------------------------------|--------------------------------|
| PERRIGO ISRAEL AGENCIES LTD | AEROPHARM GMBH, GERMANY |
| GLAXO SMITH KLINE (ISRAEL) LTD | VIIV HEALTHCARE UK LIMITED, UK |
| MEGAPHARM LTD | BAXTER ONCOLOGY GmbH, GERMANY |
| ABBVIE BIOPHARMACEUTICALS LTD, ISRAEL | ABBVIE LTD, UK |

| דרך מתן | צורת מינון |
|---------------------|---|
| הזרקה דרך השריר I.M | POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION |
| הזרקה דרך השריר I.M | POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION |
| טבליה מצופה PER OS | FILM COATED TABLETS |
| טבליה מצופה PER OS | FILM COATED TABLETS |
| טבליה מצופה PER OS | FILM COATED TABLETS |
| טבליה מצופה PER OS | FILM COATED TABLETS |
| טבליה מצופה PER OS | FILM COATED TABLETS |

| | |
|--------------|---------|
| | |
| טבליה PER OS | TABLETS |
| | |
| טבליה PER OS | TABLETS |

| | |
|-------------------|---------------------------|
| | |
| PER OS | TABLETS |
| | |
| PER OS | TABLETS |
| טבליה שחרור מושהה | TABLETS PROLONGED RELEASE |
| | |
| טבליה שחרור מושהה | TABLETS PROLONGED RELEASE |
| טבליה מצופה | FILM COATED TABLETS |
| טבליה מצופה | FILM COATED TABLETS |
| טבליה מצופה | FILM COATED TABLETS |
| טבליה מצופה | FILM COATED TABLETS |

| | |
|----------------------------------|--|
| טבליה מצופה PER OS | TABLETS |
| טבליה PER OS | TABLETS |
| טבליה מצופה PER OS | COATED TABLETS |
| תוך ורידי I.V. | POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION |
| טבליה מצופה PER OS | FILM COATED TABLETS |
| מריחה TOPICAL | CREAM |
| תרחיף PER OS | SUSPENSION |
| טבליה מצופה PER OS | COATED TABLETS |
| טבליה מצופה PER OS | COATED TABLETS |
| INTRAUTERINE התקן תוך רחמי | INTRAUTERINE DEVICE |
| תוך ורידי I.V. | CONCENTRATE FOR SOLUTION FOR INFUSION |
| תוך ורידי I.V. | CONCENTRATE FOR SOLUTION FOR INFUSION |
| תוך ורידי I.V. | SOLUTION FOR INFUSION |
| גרנולים במתן ORAL פומי | GRANULES |
| אפידורלי EPIDURAL; PERINEURAL | SOLUTION FOR INFUSION |

| | |
|---------------------|------------------------|
| טיפות עיניים OCULAR | OPHTHALMIC SOLUTION |
| טבליה מצופה PER Os | FILM COATED TABLETS |
| תוך ורידי I.V | SOLUTION FOR INJECTION |
| טבליה מצופה PER OS | FILM COATED TABLETS |

| גנרי | מרכיבים |
|------|---|
| | ARIPIRAZOLE AS MONOHYDRATE 300MG/VIAL 200 mg/ml after reconstitution |
| | ARIPIRAZOLE AS MONOHYDRATE 400MG/VIAL 200 mg/ml after reconstitution |
| | RIOCIQUAT 0.5 MG |
| | RIOCIQUAT 1 MG |
| | RIOCIQUAT 1.5 MG |
| | RIOCIQUAT 2 MG |
| | RIOCIQUAT 2.5 MG |

| | |
|------|-------------------------------|
| | |
| גנרי | ATORVASTATIN AS CALCIUM 10 MG |
| גנרי | ATORVASTATIN AS CALCIUM 20 MG |

| | |
|------|------------------------------------|
| | |
| גנרי | ATORVASTATIN AS CALCIUM 40 MG |
| | |
| גנרי | ATORVASTATIN AS CALCIUM 80 MG |
| | MIRABEGRON 25 MG |
| | |
| | MIRABEGRON 50 MG |
| | VORTIOXETINE AS HYDROBROMIDE 10 MG |
| | VORTIOXETINE AS HYDROBROMIDE 15 MG |
| | VORTIOXETINE AS HYDROBROMIDE 20 MG |
| | VORTIOXETINE AS HYDROBROMIDE 5 MG |

| | |
|------|--|
| גנרי | CARPROFEN 100 MG |
| גנרי | CARPROFEN 50 MG |
| גנרי | VALSARTAN 80 MG ; AMLODIPINE AS BESILATE 5 MG |
| | VEDOLIZUMAB 300MG/VIAL |
| | DASABUVIR 250 MG |
| | PENCICLOVIR 10MG/G |
| גנרי | IBUPROFEN 100 MG |
| | PONATINIB AS HYDROCHLORIDE 15 MG |
| | PONATINIB AS HYDROCHLORIDE 45 MG |
| | LEVONORGESTREL 13.5 MG |
| | NIVOLUMAB 10MG/ML |
| גנרי | OXALIPLATIN 5MG/ML |
| גנרי | PARACETAMOL 10MG/ML |
| | SODIUM PHENYLBUTYRATE 483MG/G |
| גנרי | ROPIVACAINE HYDROCHLORIDE 2MG/ML |

| | |
|------|---|
| גנרי | TIMOLOL AS MALEATE 5 MG ; DORZOLAMIDE AS HYDROCHLORIDE 20 MG |
| | DOLUTEGRAVIR AS SODIUM 50 MG ; ABACAVIR AS SULFATE 600 MG ; LAMIVUDINE 300 MG |
| | MESNA 400MG/VIAL |
| | RITONAVIR 50 MG ; PARITAPREVIR 75 MG ; OMBITASVIR 12.5 MG |